Objective: To systematically review reports of fingolimod persistence in the treatment of relapsing-remitting multiple sclerosis (RRMS) across data sources and practice settings, and to develop a consensus estimate of the 1-year real-world persistence rate.
Methods: A systematic literature review was conducted (MEDLINE, EMBASE, and abstracts from selected conferences [2013-2015]) to identify observational studies reporting 1-year fingolimod persistence among adult patients with RRMS (sample size ≥50). A random-effects meta-analysis was performed to estimate a synthesized 1-year persistence rate and to assess heterogeneity across studies.
Results: Of 527 publications identified, 25 real-world studies reporting 1-year fingolimod persistence rates were included. The studies included patients from different data sources (e.g., administrative claims, electronic medical records, or registries), used different definitions of persistence (e.g., based on prescriptions refills, patient report, or prescription orders), and spanned multiple geographic regions. Reported 1-year persistence rates ranged from 72%-100%, and exhibited statistical evidence of heterogeneity (I = 93% of the variability due to heterogeneity across studies). The consensus estimate of the 1-year persistence rate was 82% (95% confidence interval: 79%-85%).
Conclusions: Across heterogeneous study designs and patient populations found in real-world studies, the consensus 1-year fingolimod persistence rate exceeded 80%, consistent with persistence rates identified in the recently-completed trial, PREFERMS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jns.2018.03.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The sphingosine-1-phosphate signaling pathway (sphingosine-1-phosphate and its receptor, sphingosine kinase) and epilepsy.
Epilepsia Open
December 2024
Department of Oncology, Affiliated Hospital of Jining Medical University, Jining City, China.
Epilepsy is one of the common chronic neurological diseases, affecting more than 70 million people worldwide. The brains of people with epilepsy exhibit a pathological and persistent propensity for recurrent seizures. Epilepsy often coexists with cardiovascular disease, cognitive dysfunction, depression, etc.
View Article and Find Full Text PDFAccelerating Oral Wound Healing Using Bilayer Biomaterial Delivery of FTY720 Immunotherapy.
Adv Healthc Mater
December 2024
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Emory University, Atlanta, GA, 30322, USA.
Article Synopsis
- Orofacial clefts are the most common birth defects affecting the face, and improper healing after cleft palate surgery can result in oronasal fistulas (ONFs), which are troublesome connections between the mouth and nose.
- Current treatments using human tissue grafts for ONF repair are effective but carry risks like infection and rejection, leading to the need for further surgery.
- A new approach using an FDA-approved drug, FTY720, aims to improve healing by modifying immune responses and has shown promising results in laboratory mice, indicating potential for better treatment options in children with cleft palate issues.
Pre-existing parasympathetic dominance seems to cause persistent heart rate slowing after 6 months of fingolimod treatment in patients with multiple sclerosis.
Clin Auton Res
October 2024
Department of Neurology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, Erlangen, Germany.
Article Synopsis
- The study investigates the impact of fingolimod treatment on heart rate (HR) and cardiovascular autonomic modulation in patients with relapsing-remitting multiple sclerosis (RRMS), particularly focusing on those who initially experienced prolonged HR slowing.
- It involves monitoring 34 patients before and after fingolimod initiation, measuring various cardiovascular parameters to assess changes in autonomic function.
- Findings indicate that while all patients experienced HR decreases after treatment, those with initial prolonged HR slowing showed persistent differences in HR and autonomic modulation six months later compared to those without this phenomenon.
Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis.
Mult Scler
December 2024
Multiple Sclerosis Center, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino University Hospital, Torino, Italy.
Background: Scarce data are available on the long-term immunological effects of multiple sclerosis (MS) disease-modifying treatments (DMTs).
Objectives: This study aimed to investigate the long-term modifications of the peripheral immune repertoire on interruption of a sequestering DMT (natalizumab, fingolimod) and switch to another high-efficacy DMT.
Methods: Lymphocyte subpopulations were assessed, every 6 months up to 48 months, in patients switched from fingolimod or natalizumab to ocrelizumab, and in patients switched from fingolimod to natalizumab, compared to patients switched to ocrelizumab or natalizumab from a moderate-efficacy DMT and to naive patients.
Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments.
J Cent Nerv Syst Dis
September 2024
F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Background: Clinical trials comparing the efficacy of ocrelizumab (OCR) with other disease-modifying therapies (DMTs) other than interferon (IFN) β-1a in relapsing multiple sclerosis (RMS) are lacking.
Objectives: To compare the treatment effect of OCR vs six DMTs' (IFN β-1a, glatiramer acetate, fingolimod, dimethyl fumarate, teriflunomide, natalizumab) treatment pathways used in clinical practice by combining clinical trial and real-world data.
Methods: Patient-level data from OPERA trials and open-label extension phase, and from the German NeuroTransData (NTD) MS registry, were used to build 1:1 propensity score-matched (PSM) cohorts controlling for seven baseline covariates, including brain imaging activity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!